Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 22,444 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Pathological Processes Clear all
Completed Phase 3 Interventional Results available

A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)

NCT01621178
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Kidney Disease
Interventions
Dulaglutide, Insulin glargine, Insulin lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
47
States / cities
Montgomery, Alabama • Azusa, California • Granada Hills, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Oct 22, 2026, 1:02 AM EDT
Active, not recruiting Phase 3 Interventional

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715
View directory record Official record
Conditions
Breast Cancer; HER2-positive; Metastatic
Interventions
Trastuzumab deruxtecan, Placebo, Taxane, Pertuzumab, Trastuzumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
30
States / cities
Tucson, Arizona • Springdale, Arkansas • Glendale, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 22, 2026, 1:02 AM EDT
Recruiting Phase 2 Interventional

The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

NCT04372615
View directory record Official record
Conditions
Autoimmune Encephalitis, Encephalitis
Interventions
Inebilizumab, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
12 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 22, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional Results available

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

NCT01116232
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
anti-thymocyte globulin, rituximab, sirolimus, tacrolimus, laboratory biomarker analysis, allogeneic hematopoietic stem cell transplantation, management of therapy complications, peripheral blood stem cell transplantation
Biological · Drug · Other + 1 more
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Phase 1 Interventional

Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors

NCT04678921
View directory record Official record
Conditions
Solid Tumor, Metastatic Cancer, Advanced Cancer
Interventions
TJ210001
Drug
Lead sponsor
I-Mab Biopharma US Limited
Industry
Eligibility
18 Years to 99 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Aurora, Colorado • Lafayette, Indiana • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Anti-Inflammatory Activities of Grapes in Humans at Risk for Cardiovascular Disease

NCT01443884
View directory record Official record
Conditions
Obesity, Inflammation
Interventions
Grape powder, followed by placebo powder, Placebo powder followed by grape powder
Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
20 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2011 · Synced Oct 22, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional Results available

Preoperative Application of Chlorhexidine to Reduce Infection With Cesarean Section After Labor

NCT03423147
View directory record Official record
Conditions
Cesarean Section, Surgical Site Infection, Nosocomial Infection
Interventions
2% chlorhexidine gluconate cloth, 4% Chlorhexidine gluconate vaginal scrub
Drug
Lead sponsor
Angela Bianco
Other
Eligibility
18 Years and older · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2023 · Synced Oct 22, 2026, 1:02 AM EDT
Not listed Phase 2 Interventional

Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris

NCT00098358
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Zileuton
Drug
Lead sponsor
Critical Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
12
States / cities
San Diego, California • Newnan, Georgia • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2007 · Synced Oct 22, 2026, 1:02 AM EDT
Recruiting Phase 2 Interventional

A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)

NCT07325526
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
BI 3802876, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
26
States / cities
Chandler, Arizona • Coronado, California • La Mesa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Early Phase 1 Interventional

Gallium-68 Citrate PET Used in Prostate Cancer

NCT02391025
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Gallium-68 citrate, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Rahul Aggarwal
Other
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Not applicable Interventional Results available

Vidatalk Communication Application: Usability, Acceptability and Efficacy Study

NCT02921776
View directory record Official record
Conditions
Nonverbal Communication, Critical Illness
Interventions
Aim 1 - VidaTalk - post-extubation, Aim 2 - VidaTalk - intubated, Aim 3 - VidaTalk tablet app, Aim 3 - attention-control with non-VidaTalk tablet
Other · Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 99 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function

NCT03874117
View directory record Official record
Conditions
Hemodialysis, Kidney Failure, Chronic
Interventions
Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis, Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis
Other
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 85 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Palo Alto, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 22, 2026, 1:02 AM EDT
Terminated Not applicable Interventional Results available

Pilot Study of Brentuximab Vedotin in Relapsed/Refractory Peripheral T-Cell Lymphoma Expressing CD30

NCT01841021
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma
Interventions
Brentuximab vedotin
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 22, 2026, 1:02 AM EDT
Completed No phase listed Observational

Restore EF Observational Study

NCT04648306
View directory record Official record
Conditions
Coronary Artery Disease, Unstable Angina, Angina, Stable, NSTEMI - Non-ST Segment Elevation MI
Interventions
Prophylactic Impella support for a non-emergent PCI
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Phase 2 Interventional

131MIBG to Treat Malignant Pheochromocytoma

NCT00028106
View directory record Official record
Conditions
Pheochromocytoma
Interventions
[131]I-MIBG, 6-[18F]Fluorodopamine, [123]I-MIBG
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 22, 2026, 1:02 AM EDT
Terminated Phase 2 Interventional

The Effects of Nitric Oxide for Inhalation in Right Ventricular Infarction Patients

NCT00782652
View directory record Official record
Conditions
Right Ventricular Infarction
Interventions
inhaled nitric oxide, nitrogen gas
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
Boston, Massachusetts • Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 22, 2026, 1:02 AM EDT
Recruiting Not applicable Interventional

Pulsed Electromagnetic Field (PEMF) Therapy for Post-operative Pain Following Orthopedic Surgery

NCT04109638
View directory record Official record
Conditions
Knee Injuries, Shoulder Injuries, Pain, Postoperative
Interventions
Endonovo SofPulse
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 22, 2026, 1:02 AM EDT
Active, not recruiting Phase 3 Interventional

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

NCT03844048
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia, Multiple Myeloma, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Cancer
Interventions
Venetoclax
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Not listed
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
7
States / cities
Tucson, Arizona • Los Angeles, California • Harvey, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 22, 2026, 1:02 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF

NCT04956978
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Patient Decision Support Tool
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 1:02 AM EDT
Recruiting No phase listed Observational

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

NCT01137643
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nonmalignant Neoplasm
Interventions
biologic sample preservation procedure, cytology specimen collection procedure
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2040
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Oct 22, 2026, 1:02 AM EDT
Withdrawn No phase listed Observational

Carotid Plaque Regression With Statin Treatment Assessed by High Field Magnetic Resonance Imaging (MRI)

NCT00388843
View directory record Official record
Conditions
Carotid Atherosclerosis
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 22, 2026, 1:02 AM EDT
Completed No phase listed Observational

Regulation of Cerebral Blood Flow in Very Low Birth Weight Infants

NCT00579943
View directory record Official record
Conditions
Infant, Very Low Birth Weight, Infant, Premature, Diseases, Cerebral Hemorrhage
Interventions
Not listed
Lead sponsor
University of Arkansas
Other
Eligibility
1 Hour to 7 Days
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2008 · Synced Oct 22, 2026, 1:02 AM EDT
Withdrawn Not applicable Interventional

Efficacy Study of Prednisone Priming to Treat Asian Chronic Hepatitis B Patients

NCT00715715
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
Prednisone Priming
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 20, 2012 · Synced Oct 22, 2026, 1:02 AM EDT
Completed Phase 1 Interventional

Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration

NCT00001615
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Corticosteroid
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 22, 2026, 1:02 AM EDT